Read more about Stocks to watch: M&M, Sun Pharma, Eicher Motors, Glenmark Pharma on Business Standard. Analysts expect M&M to report up to 330 per cent YoY growth in net profit, helped by increase in volume and average selling price
Stock market movers: Top 10 winners and losers on BSE, NSE on May 28 freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Read more about Sun Pharma Q4 net more than doubles to Rs 894 cr on better operational show on Business Standard. Low base supported overall performance; consolidated sales from operations came in at Rs 8,431 crore, up 4.4% YoY
›Sun Pharma Q4 results: Consolidated PAT rises 123% YoY to Rs 894 cr, misses estimates; board to pay Rs 2 dividend
Sun Pharma Q4 results: Consolidated PAT rises 123% YoY to Rs 894 cr, misses estimates; board to pay Rs 2 dividend
SECTIONS
Sun Pharma Q4 results: Consolidated PAT rises 123% YoY to Rs 894 cr, misses estimates; board to pay Rs 2 dividendETMarkets.com
Last Updated: May 27, 2021, 04:45 PM IST
Share
Synopsis
The big miss on the bottomline by the company was a result of an exceptional loss worth Rs 672.8 crore related to various litigation settlements pertaining to some of its subsidiaries.
The company’s consolidated revenue from operations rose merely 4 per cent on-year to Rs 8,523 crore, which was also below analysts’ expectations of Rs 8,712.5 crore.
COVID-19: Bal Pharma supplies Favipiravir under brand name BALflu for Rs 85 per tablet in India freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.